Search

Displaying results 1541 - 1550 of 1723 in total
  1. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections.

  2. Drug

    Detomidine

    go.drugbank.com/drugs/DB11556
    InvestigationalVet approved

    Currently, it is only approved by the FDA for use in horses but has been studied for use in other large animals.

  3. Drug

    Melatonin

    go.drugbank.com/drugs/DB01065
    ApprovedInvestigationalNutraceuticalVet approved

    Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the ...

  4. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer [L1295]. … Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant

  5. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    This drug from BMS was not approved by the FDA due to angioedema safety concerns.

  6. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCL...

  7. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021.

  8. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461]

  9. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis.

  10. Drug

    Etryptamine

    go.drugbank.com/drugs/DB01546
    ApprovedIllicitWithdrawn

    1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was an FDA